01Principles and purposeThe professional or clinical skill and the decisions it supports.
Monitoring is a prospective clinical plan rather than a list of blood tests. Before treatment starts, decide which useful effect and which important harm can be assessed, how quickly either may develop and what action will follow a finding. Some effects are measured directly, such as blood pressure or glucose; others require a laboratory surrogate or a timed medicine concentration. The observation must be capable of changing care. Repeating a test automatically without understanding the medicine’s risk can produce unnecessary burden, false reassurance or an abnormal result that no one knows how to interpret.
Timing gives monitoring its clinical meaning. A baseline establishes whether treatment is suitable and provides a comparator. An early post-initiation test looks for a change caused by the medicine, while stable surveillance detects longer-term toxicity or altered physiology. Acute illness can invalidate the assumptions behind a routine schedule and require immediate reassessment. A person taking lithium who develops vomiting and ataxia should not be told that their annual review is not due, just as an ACE-inhibitor dose change should not proceed indefinitely without checking renal and electrolyte response. The plan must be specific enough to work when the original prescriber is away.
Key points
- A complete monitoring plan states what to measure, when to measure it, why it matters, what result or symptom changes treatment and who will act.
- Distinguish baseline assessment, early checks after initiation or dose change, stable surveillance and urgent testing during illness; these are different monitoring situations.
- For ACE inhibitor or ARB treatment, check blood pressure, kidney function, sodium and potassium before initiation, then repeat the relevant laboratory tests within 1–2 weeks, earlier when risk is higher.
- In stable CKD, NICE advises no dose modification for a creatinine increase below 30% or eGFR reduction below 25%, with repeat testing in 1–2 weeks; interpret this alongside symptoms, potassium and the actual clinical setting.
- Use a timed drug concentration only with the dose history and sampling information needed to interpret it. Lithium usually requires a 12-hour post-dose comparison sample.
- Do not wait for the next scheduled surveillance test when toxicity symptoms, acute illness or a significant interaction changes risk.
- Close the result-handling loop: review, act, communicate and confirm follow-up. Ordering a test without an accountable reader does not establish safe monitoring.
02Situations and prioritiesThe context, relevant information and actions that matter most.
Define what success would look like for the medicine and indication. A lower laboratory value is not always the main aim; symptom control, seizure prevention, fewer exacerbations or improved function may be more meaningful. The chosen efficacy measure should be interpretable over the interval at which it will be reassessed.
Use the medicine’s mechanism, product information and patient factors to select safety monitoring. Kidney impairment, interacting drugs, age and acute illness can increase the frequency needed. Distinguish an adverse effect detectable by blood tests from one that requires asking about symptoms or observing function.
Starting another medicine, a dose increase, dehydration, weight loss or a new organ problem may justify additional monitoring even if the last scheduled result was satisfactory. Ask what changed since that result. A previously stable treatment label should not prevent a fresh risk assessment.
Symptoms, rapid trends or a markedly abnormal result may require urgent contact and treatment rather than a routine repeat. Assess the person and the next dose decision together. Repeating a concerning test without an interim plan can leave the patient exposed while the team waits for confirmation.
03Assessment and interpretationHow to gather information, assess the situation and recognise uncertainty.
Consider the information, its meaning and its limitations before deciding what follows.
- 01
Baseline measurements relevant to the medicine - Why
- Determine suitability and create a comparator for future changes.
- Interpretation and limitations
- Record the actual baseline value and date rather than simply marking bloods normal. For an ACE inhibitor, kidney function and potassium influence both initial suitability and interpretation of the subsequent response. The baseline should be recent enough to reflect the patient’s state when treatment begins.
- 02
An appropriately timed early review - Why
- Detect the expected treatment response and early toxicity.
- Interpretation and limitations
- Use the medicine-specific interval and shorten it when patient risk is higher. A test taken before a meaningful effect can develop may not answer the intended question, while a delayed test can miss an important deterioration. Ensure the patient can attend and knows whether any dose-timing instruction applies.
- 03
Trend and percentage-change calculation - Why
- Interpret a new value against a clinically relevant previous result.
- Interpretation and limitations
- Calculate percentage change using the original baseline as the denominator. A creatinine rise from 100 to 118 micromol/L is 18%, not 118%. Review absolute severity, direction, symptoms and accompanying results as well as the percentage; the same arithmetic can require different action in stable CKD and acute illness.
- 04
Timed concentrations with administration metadata - Why
- Avoid interpreting a drug level against an incompatible target.
- Interpretation and limitations
- State the medicine, dose, formulation, last administration and sample time, plus recent missed doses or changes. A laboratory can accurately measure a concentration without knowing that it was obtained at the wrong point in the dosing interval. The clinical team must supply that context and decide whether the comparison is valid.
04Worked approachesCases with ordered reasoning, an action and a check of the outcome.
01Worked exampleInterpret an early ACE-inhibitor check in stable CKDA 58-year-old with stable CKD G3a and hypertension starts ramipril 2.5 mg orally daily. Baseline creatinine is 100 micromol/L, eGFR 58 mL/min/1.73 m² and potassium 4.3 mmol/L. At 10 days, creatinine is 118, eGFR 49 and potassium 4.8; pressure is 132/76 mmHg, with no dizziness, dehydration, acute illness or new interacting medicine.+
- 1Confirm that the test was obtained in the intended early monitoring window and that the supplied clinical stability is accurate. The current potassium and pressure do not themselves provide a reason for emergency withholding in this case.
- 2Calculate creatinine change: (118 − 100) ÷ 100 × 100 = 18%. Calculate eGFR reduction: (58 − 49) ÷ 58 × 100 ≈ 15.5%. Both are below the NICE stable-CKD thresholds of 30% creatinine increase and 25% eGFR reduction.
- 3Apply the stable-CKD guidance to the supplied patient: continue the current ramipril dose without an automatic reduction and arrange repeat kidney function and potassium in 1–2 weeks. Do not turn this decision into a universal rule for symptomatic acute kidney injury or a different heart-failure context.
- 4Give the final plan with a named result reviewer, the repeat-test date and advice to contact the team if illness or dizziness develops. Independently verify the arithmetic against the original baseline and confirm that the prescription remains 2.5 mg daily while the repeat response is assessed.
02Monitoring designCreate a usable plan before a high-risk medicine startsA medicine requires ongoing efficacy and safety surveillance.+
- 1List the minimum baseline information that establishes suitability, then identify the early and long-term adverse effects that can be detected. Choose observations and tests that match those effects rather than copying every test from a generic high-risk-drug template.
- 2Specify the first review and what should happen after dose changes, interactions or acute illness. For a medicine concentration, add the exact relation between dose and sample so that the phlebotomy appointment can be booked correctly.
- 3State how results and symptoms will change treatment, including when urgent assessment is needed and whether the next dose should be withheld pending advice. Where thresholds depend on the indication or local protocol, identify the actual guidance the reviewing clinician should use.
- 4Assign the prescriber, test requester and result reviewer, including cover when the usual clinician is absent. Give the patient the schedule, purpose and contact instructions, and confirm that attendance and transport are feasible.
03Abnormal resultAct on a monitoring result that changes riskA result is unexpectedly abnormal or is accompanied by possible toxicity symptoms.+
- 1Check patient identity, units, sample timing and previous values, then assess clinical severity. Verification should run alongside urgent patient contact when the result could indicate serious harm; do not postpone necessary care until every administrative uncertainty is resolved.
- 2Identify the medicines and physiological changes that could explain the finding. Review actual doses, recent interactions, kidney or liver function and illness, and decide whether the next administration remains safe while the cause is assessed. If lithium toxicity symptoms are present, withhold lithium, obtain an urgent lithium concentration and U&Es, and seek specialist advice without waiting for routine 12-hour sampling.
- 3Implement the appropriate repeat test, dose change, temporary hold, treatment or specialist referral. Record the rationale in terms of the medicine and patient, rather than copying a laboratory flag as though it were a complete management instruction.
- 4Communicate the result and action to the patient and relevant clinicians. Arrange confirmation that the intervention worked and a deliberate restart or alternative plan when treatment was withheld, so monitoring does not end with an unresolved interruption.
05Feedback, follow-up and evidenceReview outcomes, seek feedback and identify what to improve.
- Review whether the monitoring plan itself is being completed. Missed blood tests, repeated booking problems or results sent to an inactive clinician require a system response; extending repeat prescriptions without resolving the gap can perpetuate risk.
- After an initially acceptable biochemical change, follow the recommended repeat interval and trajectory. Stability on the second test supports a different conclusion from continuing deterioration despite an apparently modest first change.
- For lithium, stable concentration checks generally occur every 3–6 months, with renal, thyroid and calcium assessment every 6 months and more frequent review for higher-risk circumstances. Symptoms can trigger urgent testing independently of these schedules.
- For digoxin, routine levels are not recommended without a clinical question. Renal function, electrolytes, pulse and symptoms may be more useful ongoing observations, while a timed concentration helps when toxicity, interaction or altered exposure is suspected.
06Special situationsVariants, exceptions and circumstances that change the usual approach.
A threshold is part of a pathway
A percentage criterion has meaning only within the patient group and clinical context for which it is used. Record whether the decision concerns stable CKD, heart failure or acute deterioration before applying a remembered stopping rule.
The baseline denominator matters
Percentage increase is the change divided by the original value. Using the new value as the denominator understates a rise and can move a result across a decision threshold, even though both numbers came from the correct patient.
A normal result can be stale
A satisfactory value obtained before a new interaction or illness does not describe the resulting risk. Monitoring should respond to changes in exposure and physiology rather than treating the date of the next routine test as fixed.
Ownership is a clinical safety measure
A result that arrives without a responsible reviewer may fail to change treatment. Naming the reviewer and cover arrangement is as necessary as choosing the correct test, especially when care crosses organisational boundaries. A shared-care arrangement should also specify what happens when a test is missed and whether further supply is appropriate, so responsibility is not negotiated for the first time after an overdue high-risk prescription request.
07Common pitfallsFrequent interpretation and management errors.
- 01
Ordering follow-up blood tests without specifying who receives and acts on them can leave significant abnormalities unaddressed.
- 02
Applying a stable-CKD percentage rule to a patient with acute illness and poor perfusion can falsely reassure despite a clinically important deterioration.
- 03
Comparing a mistimed drug concentration with a trough target can provoke an unnecessary or unsafe dose change.
- 04
Treating every abnormal laboratory flag as an instruction to stop treatment ignores indication, magnitude, symptoms and the possibility of an expected monitored response.